Investor Center Home


Corporate Profile
Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.

More >>

BLCM (Common Stock)
(US Dollar)
Price$11.29
Change Stock is Down 0.5
(%)Volume (4.24%)839,853
ExchangeNASDAQ
Data as of 09/21/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
DateTitle 
08/30/17Bellicum Pharmaceuticals to Present at Three Healthcare Investor Conferences in SeptemberPrinter Friendly Version
08/08/17Bellicum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate UpdatePrinter Friendly Version
08/03/17Bellicum Pharmaceuticals Appoints Gregory Naeve as Chief Business OfficerPrinter Friendly Version
08/01/17Bellicum Pharmaceuticals to Report Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8, 2017Printer Friendly Version
More >>
Upcoming Events
09/26/17 12:00 p.m. ET
Bellicum Pharmaceuticals Inc at Ladenburg Thalmann 2017 Healthcare Conference
Click here for webcast
10/04/17 2:30 p.m. PT
Bellicum Pharmaceuticals Inc at 2017 Cell & Gene Meeting on the Mesa
Click here for webcast
Past Events
09/06/17 3:00 p.m. ET
Bellicum Pharmaceuticals Inc at 2017 Wells Fargo Securities Healthcare Conference
Click here for webcast
08/08/17 5:00 p.m. ET
Q2 2017 Bellicum Pharmaceuticals Earnings Conference Call
Click here for webcast
More >>
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources